ABL Diagnostics Signs Letter of Intent for Reverse Merger with ProPhase Labs
ABL Diagnostics announces the signing of a non-binding letter of intent between its controlling shareholder ABL S.A. and the Nasdaq-listed American company ProPhase Labs, aimed at a reverse merger project. According to the statement, ABL would become the majority shareholder of the combined entity resulting from this transaction.
The letter of intent signed between Advanced Biological Laboratories S.A., the controlling shareholder of ABL Diagnostics, and ProPhase Labs is preliminary in nature, the company states. The document does not carry any obligation to conclude the transaction, except for usual provisions relating to confidentiality and cost coverage. The project remains subject to several conditions, according to the group, including the completion of due diligence, negotiation and signing of definitive agreements, obtaining regulatory approvals, and meeting Nasdaq listing requirements. The parties aim for a timeline of 60 to 90 days to sign the definitive agreements, as per the statement. In the absence of signing definitive agreements, each party will continue its operations independently.
Impact on Corporate Control and Regulatory Requirements
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Based on the information available, the project does not affect the control of ABL Diagnostics by ABL S.A. and does not trigger a mandatory public offer threshold, the company indicates. However, ABL Diagnostics states that it will review all aspects of the transaction with its advisors and, if necessary, will notify the Financial Markets Authority and seek an exemption. On the American side, the transaction may require the approval of ProPhase shareholders in case of a change of control or an issuance of shares exceeding 20 percent of the capital, the statement specifies. ProPhase remains responsible for its compliance with Nasdaq and Securities and Exchange Commission regulations.
Details about ProPhase Labs and the Proposed Transaction
ProPhase Labs is an American company listed on Nasdaq under the ticker PRPH. The proposed transaction would take the form of a reverse merger, a financial technique whereby an unlisted company takes control of a listed company, thus allowing the former to access the financial markets. In this case, ABL would become the majority shareholder of the entity resulting from the merger, according to the statement. ABL Diagnostics, headquartered in Woippy, France, specializes in innovative molecular biology testing and markets its product range globally. The company is listed on compartment B of the regulated market of Euronext in Paris.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 13,8 millions d'euros
Management commentary: Sur la base des informations commerciales, opérationnelles et comptables disponibles à la date du présent communiqué, la Société anticipe désormais un chiffre d'affaires compris entre 13,5 M€ et 14,0 M€. Cette fourchette actualise l'objectif de 12,265 M€ publié le 1er juin 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
